The weight-loss drug rivalry heats up as another GLP-1 pill gains FDA approval – Scientific American
FDA approves another oral GLP-1 drug, intensifying competition in the booming weight-loss medication market.
-
-
What Took So Long? Estrogen Patches and the Shift Reshaping Menopause Care – Kansas City Star
Estrogen patches are reshaping menopause care as evidence shows safer cardiovascular profile than oral hormone therapy.
-
ProHealth Longevity BPC‑157 Claims Evaluated: Most Effective BPC157 Peptide Brand on the Market (2026) – Yahoo Finance
ProHealth Longevity claims its BPC-157 peptide leads the market, though the compound remains unapproved and lacks human clinical trials.
-
Oasis Medical Clinic & Spa Launches Advanced Peptide Therapy in McKinney, TX – heraldtribune.com
McKinney medical spa introduces peptide therapy services amid growing interest in regenerative wellness treatments.
-
Indirect Analysis Suggests Greater Weight Loss With Oral Semaglutide vs Orforglipron – HCPLive
New indirect analysis suggests oral semaglutide produces greater weight loss than orforglipron in comparative review.
-
Wolverine in a vial: Inside the risky, unregulated world of peptides – AFR
Unregulated peptide therapies proliferate despite safety concerns and lack of approval, AFR investigation reveals.
-
Most anti-ageing peptides don’t work. But these might – BBC Science Focus Magazine
BBC investigation reveals most anti-ageing peptides lack evidence, but GHK-Cu and Matrixyl show genuine promise in clinical research.
-
HRT’s Role in Skin Health During Menopause – physiciansweekly.com
Hormone replacement therapy may help preserve skin collagen and elasticity during menopause when estrogen levels decline significantly.
-
FDA approves Eli Lilly’s GLP-1 pill, opening the next phase of the weight loss drug market – CNBC
FDA approves first oral GLP-1 medication for weight loss, offering pill alternative to injections like Wegovy and Zepbound.
-
FDA approves Lilly’s Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions – Eli Lilly
FDA approves Foundayo, the first GLP-1 weight loss pill that can be taken anytime without food or water restrictions.
